This website uses cookies to improve your experience. Continue if you are OK with this or read more in our privacy policy. 

Bristol-Myers Squibb loses Baraclude patent fight with Teva


A US judge has invalidated pharmaceutical company Bristol-Myers Squibb (BMS)’s patent covering its hepatitis B treatment Baraclude, agreeing with generic manufacturer Teva Pharmaceuticals that the invention of the active compound in the drug was obvious to anyone skilled in medicinal chemistry.

Bristol-Myers, Teva, Baraclude, patent, generic, invalid, obvious


Payment types accepted